Research Currently Recruiting

Research Currently Recruiting

 

The following is a list of research studies currently recruiting patients.

For more information or if you are interested in participating in any of the research studies below, please leave a voicemail for our research team at 206-320-2200.


CONCERTO

A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS).

Sponsor: Teva Pharmaceuticals Industries Ltd

Type of MS: Relapsing-Remitting

Contact: Beena Gangadharan, (206) 320-2633

More Information
 


EXPAND

A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

Sponsor: Novartis Pharmaceuticals Corporation

Type of MS: Secondary-Progressive

Contact: Beena Gangadharan, (206) 320-2633

More Information
 


SYNERGY

Study to assess the efficacy, safety, tolerability, and pharmacokinetics of BIIB033 in subjects with relapsing forms of multiple sclerosis when used concurrently with Avonex ®.


Type of MS:  Relapsing-Remitting 

Contact: Yuriko Courtney, (206) 320-2647

More Information

 


CENSUM

A phase 1 randomized study of MEDI-551 in subjects with relapsing-remitting multiple sclerosis.

Sponsor:  MedImmune, LLC

Type of MS:  Relapsing-Remitting

Contact:  Beena Gangadharan, (206) 320-2633

More Information
 


TCELNA

A phase 2 double-blind, placebo controlled multi-center study to evaluate the efficacy and safety of Tcelna™ in subjects with secondary progressive multiple sclerosis.

Sponsor: Opexa Therapeutics, Inc

Types of MS: Secondary-Progressive

Contact : Yuriko Courntey, (206) 320 2647

More information
 


VACCINEX

A phase I, multicenter, randomized, double-blind, placebo-controlled, ascending single-dose study of the safety, tolerability and pharmacokinetics of intravenous VX15/2503 in patients with multiple sclerosis.

Sponsor:  Vaccinex Inc.

Type of MS:  Any type of MS

Contact:  Beena Gangadharan (206) 320-2633

More Information



LOW DOSE FINGOLIMOD

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.
 
Sponsor:  Novartis Pharmatheuticals Corporation

Type of MS:  Relapsing Remitting MS

Contact:  Colleen Ottinger (206) 320-3695

More Information
 


RESPOND

A multicenter, open-label, 12-month observational study evaluating the clinical effectiveness and impact on patient-reported outcomes of oral Tecfidera™ (dimethyl fumarate) delayed-release capsules in patients with relapsing forms of multiple sclerosis after suboptimal response to glatiramer acetate.

Sponsor:  Biogen Idec

Type of MS:  Relapsing Form of MS

Contact:  Lauren Lennox (206) 320-4355
 


COLLABORATIVE STUDY WITH UW

Quantitative imaging of white and gray matter demyelination in multiple sclerosis using macromolecular proton fraction mapping.

Sponsor:  National MS Society

Type of MS:  Secondary Progressive MS or RRMS

Contact:  Beena Gangadharan (206) 320-2633
 


SPRINT MS

Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and activity of Ibudilast (MN-166) in subjects with progressive multiple sclerosis.

Sponsor:  National Institutes of Health

Type of MS:  Primary Progressive and Secondary Progressive MS

Contact: Beena Gangadharan (206) 320-2633
 


RR = relapsing remitting, SP = secondary progressive, PP = primary progressive, CIS = clinicaly isolated syndrome

 

Contact Information

Multiple Sclerosis Center
1600 East Jefferson
A Level
Seattle, WA 98122
Phone: 206-320-2200
Fax: 206-320-2560

How You Can Help

Swedish is constantly working to ensure patients with debilitating neurological disorders have access to the best treatment options, the latest technology, and state-of-the-art facilities.

Learn more

 

Driving Directions


Ask us about discounted valet